We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00152386
Recruitment Status : Completed
First Posted : September 9, 2005
Last Update Posted : December 1, 2020
Information provided by:
UCB Pharma

Brief Summary:
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: Certolizumab pegol (CDP870) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 950 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate
Study Start Date : February 2005
Actual Primary Completion Date : October 2006
Actual Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. To assess the efficacy of CDP870 in combination with Methotrexate in the treatment of Rheumatoid Arthritis and prevention of structural damage by measuring the ACR20 response at week 24 and change from Baseline

Secondary Outcome Measures :
  1. Change from Baseline in mTSS at week 24, Change from Baseline in HAQ-DI at weeks 24 and 52, ACR20 responder rate at week 52, ACR50 and ACR70 responder rate at weeks 24 and 52

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female, aged at least 18 years old at the Screening visit.
  • A clear chest X-ray within 3 months prior to Baseline visit.
  • A diagnosis of adult-onset RA (of at least six months duration but not longer than 15 years prior to Screening) as defined by the 1987 American College of Rheumatology classification criteria.
  • Active RA disease at Screening and Baseline as defined by:

    • ≥9 tender joints.
    • ≥9 swollen joints. and fulfilling 1 of the following 2 criteria:
    • ≥30 mm/hour ESR (Westergren), or
    • CRP >15 mg/L.
  • Must have received a stable dose of MTX with or without folic acid for at least 3 months prior to Baseline visit. The minimum dose is 10 mg MTX weekly.
  • Patient must be willing to attend for a Week 52 X-ray of the hands and feet even if they are no longer receiving study treatment but have not withdrawn their informed consent.

Exclusion Criteria:

  • A diagnosis of any other inflammatory arthritis e.g., psoriatic arthritis or ankylosing spondylitis.
  • A secondary, non-inflammatory type of arthritis (e.g. OA or fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of CDP870 on the patient's primary diagnosis of RA.
  • A history of an infected joint prosthesis at any time with prosthesis still in situ.
  • Does not meet exclusionary concomitant medication criteria.
  • A history of a lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease at any time.
  • Patients at a high risk of infection in the Investigator's opinion (e.g. leg ulcers, indwelling urinary catheter and persistent or recurrent chest infections).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00152386

Show Show 79 study locations
Sponsors and Collaborators
UCB Pharma
Layout table for investigator information
Study Director: UCB Clinical Trial Call Center UCB Pharma
Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00152386    
Other Study ID Numbers: C87027
2004-002993-49 ( EudraCT Number )
First Posted: September 9, 2005    Key Record Dates
Last Update Posted: December 1, 2020
Last Verified: November 2020
Keywords provided by UCB Pharma:
Rheumatoid Arthritis, CDP870
Certolizumab pegol, Cimzia
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Certolizumab Pegol
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents